1,797
Views
0
CrossRef citations to date
0
Altmetric
Neurology

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, , , , , , , , , , , , , , ORCID Icon, ORCID Icon, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , & show all
Pages 109-125 | Received 28 Jul 2023, Accepted 07 Dec 2023, Published online: 26 Dec 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.